India Globalization Capital, Inc. (IGC)
$
0.33
Key metrics
Financial statements
Free cash flow per share
-0.0645
Market cap
26.8 Million
Price to sales ratio
21.7200
Debt to equity
0.0431
Current ratio
1.1483
Income quality
0.5212
Average inventory
1.5 Million
ROE
-1.2219
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
The total costs and expenses for the company are $11,143,000.00 reflecting its overall spending. The weighted average number of diluted shares outstanding is 58,839,868.00 indicating potential dilution effects that may impact shareholders. Additionally, the company incurred an interest expense of $0.00 which highlights its debt servicing obligations. Despite its efforts, the company reported a net loss of -$13,000,000.00 indicating challenges in its operations that it must navigate moving forward. The financial data pertains to the fiscal year 2024 which provides a framework for assessing its performance during this period. India Globalization Capital, Inc. purchases and resells physical infrastructure commodities and operates through two segments, Infrastructure and Life Sciences. The company rents heavy construction equipment and undertakes highway construction contracts while also developing cannabinoid-based products and therapies. The stock is affordable at $0.33 making it suitable for budget-conscious investors looking for entry-level opportunities. However, the stock has a low average trading volume of 288,006.00 suggesting lower market activity and possibly less liquidity for traders. With a market capitalization of $26,080,966.00 the company is classified as a small-cap player, which often appeals to investors interested in potential growth outside of larger corporations. It is a key player in the Conglomerates industry, contributing significantly to the overall market landscape through diverse operational segments. Furthermore, it belongs to the Industrials sector, driving innovation and growth in both physical infrastructure and cannabinoid-related markets. As it continues to expand its offerings and navigate financial challenges, the company exemplifies a blend of traditional and emerging industry practices.
Is India Globalization Capital, Inc. (IGC) a good investment?
Investing in India Globalization Capital, Inc. (IGC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is India Globalization Capital, Inc. (IGC)'s stock forecast?
Analysts predict India Globalization Capital, Inc. stock to fluctuate between $0.25 (low) and $0.55 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is India Globalization Capital, Inc.'s market capitalization?
As of 2025-05-28, India Globalization Capital, Inc.'s market cap is $26,080,966, based on 79,685,200 outstanding shares.
How does India Globalization Capital, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., India Globalization Capital, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy India Globalization Capital, Inc. (IGC) stock?
To buy India Globalization Capital, Inc. (IGC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for IGC. Place an order (Market, Limit, etc.).
What is the best time to invest in India Globalization Capital, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has India Globalization Capital, Inc. stock ever split?
India Globalization Capital, Inc.'s last stock split was 1:10 on 2013-04-19.
How did India Globalization Capital, Inc. perform in the last earnings report?
Revenue: $1,345,000 | EPS: -$0.22 | Growth: -0%.
Where can I find India Globalization Capital, Inc.'s investor relations reports?
Visit https://www.igcinc.us/investor-relations for detailed financial reports.
Where can I find historical stock prices for India Globalization Capital, Inc.?
You can explore historical data from here
What is the all-time high and low for India Globalization Capital, Inc. stock?
All-time high: $4.65 (2021-07-22) | All-time low: $0.25 (2023-12-20).
What are the key trends affecting India Globalization Capital, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
accessnewswire.com
POTOMAC, MD / ACCESS Newswire / May 22, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced a clinical trial site at Santa Cruz Behavioral in Puerto Rico for its CALMA Phase 2 clinical trial, investigating IGC-AD1 for agitation in Alzheimer's disease. This strategic site directly addresses the significant impact of Alzheimer's in the region.
accessnewswire.com
POTOMAC, MD / ACCESS Newswire / May 12, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that it presented its latest scientific poster, titled "Genetic Toxicity Evaluation of Melatonin in the Bacterial Reverse Mutation Assay," at the 2025 Genetic Toxicology Association Annual Meeting, showcasing key non-clinical data that support the genetic safety profile of one of the two active pharmaceutical ingredients ("API") in IGC-AD1, the Company's investigational drug for Alzheimer's disease. Part of the FDA's battery of safety requirements is to show that APIs are safe for human consumption, including that they do not alter or mutate genes.
accessnewswire.com
POTOMAC, MARYLAND / ACCESS Newswire / April 24, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that the Company's recently appointed advisors entered into a Share Purchase Agreement (the "SPA") on April 21, 2025, for the purchase of common shares from the Company. The investment, subject to the terms and conditions set forth in the SPA, is for approximately $475 thousand at the higher of 30 cents or $0.01 over the last closing price.
accessnewswire.com
Industry Veterans Bring Deep Strategic Experience to Guide Alzheimer's Clinical Expansion and Commercial Strategy POTOMAC, MARYLAND / ACCESS Newswire / April 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the addition of Frank Zaccanelli, Robert K. Coughlin, and Joseph Mangan to its Board of Advisors.
accessnewswire.com
POTOMAC, MARYLAND / ACCESS Newswire / April 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the expansion of its ongoing Phase 2 CALMA clinical trial with the addition of Butler Hospital's Memory and Aging Program, a nationally recognized research center affiliated with the Warren Alpert Medical School of Brown University, in Providence, Rhode Island. The site will support enrollment for the CALMA study evaluating IGC-AD1, IGC Pharma's investigational therapy for agitation in Alzheimer's disease, a condition affecting a majority of Alzheimer's patients and significantly impacting caregivers.
accessnewswire.com
POTOMAC, MD / ACCESS Newswire / March 4, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced an advancement in its Artificial Intelligence ("AI") platform with the development of a new AI-driven model designed to improve the diagnosis of Alzheimer's disease (AD) and other causes of dementia. With Alzheimer's accounting for approximately 60-80% of all dementia cases, alongside other conditions such as vascular disease, Lewy body disease, and frontotemporal degeneration, accurate diagnosis is critical to ensuring the right treatment strategy.
accessnewswire.com
POTOMAC, MARYLAND / ACCESS Newswire / February 18, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results for the third fiscal quarter of 2025 ended December 31, 2024. "The third quarter of fiscal 2025 was marked by our progress in advancing IGC-AD1 in our Phase 2 CALMA trial aimed at reducing agitation in Alzheimer's," said Mr.
zacks.com
IGC Pharma, Inc. (IGC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.09 per share a year ago.
zacks.com
IGC Pharma, Inc. (IGC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
accessnewswire.com
POTOMAC, MD / ACCESS Newswire / January 28, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is proud to announce its selection as one of the top 15 finalists in the PREPARE Challenge - Phase 2: Model Arena (Acoustic Track), organized by the National Institute on Aging (NIA). This recognition highlights IGC's innovative application of artificial intelligence (AI) and machine learning to advance early detection of Alzheimer's disease (AD) and improve patient outcomes.
See all news
